184 related articles for article (PubMed ID: 32941398)
1. Therapeutic Monitoring of Lacosamide in Japanese Patients With Epilepsy: Clinical Response, Tolerability, and Optimal Therapeutic Range.
Yamamoto Y; Terada K; Araki Y; Fukushima Y; Imai K; Kagawa Y; Takahashi Y
Ther Drug Monit; 2020 Oct; 42(5):754-759. PubMed ID: 32941398
[TBL] [Abstract][Full Text] [Related]
2. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs.
Sake JK; Hebert D; Isojärvi J; Doty P; De Backer M; Davies K; Eggert-Formella A; Zackheim J
CNS Drugs; 2010 Dec; 24(12):1055-68. PubMed ID: 21090839
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, tolerability, and clinical effectiveness of perampanel in Japanese patients with epilepsy.
Yamamoto Y; Shiratani Y; Asai S; Usui N; Nishida T; Imai K; Kagawa Y; Takahashi Y
Seizure; 2020 Dec; 83():181-186. PubMed ID: 33171342
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience combined with therapeutic drug monitoring of lacosamide.
Svendsen T; Brodtkorb E; Baftiu A; Lossius MI; Nakken KO; Johannessen SI; Johannessen Landmark C
Acta Neurol Scand; 2020 Apr; 141(4):279-286. PubMed ID: 31853958
[TBL] [Abstract][Full Text] [Related]
5. Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs.
Markoula S; Teotonio R; Ratnaraj N; Duncan JS; Sander JW; Patsalos PN
Ther Drug Monit; 2014 Aug; 36(4):494-8. PubMed ID: 24562047
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized, double-blind trial.
Schmitz B; Dimova S; Zhang Y; Chellun D; De Backer M; Gasalla T
Epilepsy Res; 2020 Jan; 159():106220. PubMed ID: 31812127
[TBL] [Abstract][Full Text] [Related]
7. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M
Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534
[TBL] [Abstract][Full Text] [Related]
8. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction?
Novy J; Patsalos PN; Sander JW; Sisodiya SM
Epilepsy Behav; 2011 Jan; 20(1):20-3. PubMed ID: 21056937
[TBL] [Abstract][Full Text] [Related]
9. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Nevitt SJ; Sudell M; Cividini S; Marson AG; Tudur Smith C
Cochrane Database Syst Rev; 2022 Apr; 4(4):CD011412. PubMed ID: 35363878
[TBL] [Abstract][Full Text] [Related]
10. Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.
Contin M; Albani F; Riva R; Candela C; Mohamed S; Baruzzi A
Ther Drug Monit; 2013 Dec; 35(6):849-52. PubMed ID: 23942540
[TBL] [Abstract][Full Text] [Related]
11. AntiEpileptic drug Monitoring in PREgnancy (EMPiRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies.
Thangaratinam S; Marlin N; Newton S; Weckesser A; Bagary M; Greenhill L; Rikunenko R; D'Amico M; Rogozińska E; Kelso A; Hard K; Coleman J; Moss N; Roberts T; Middleton L; Dodds J; Pullen A; Eldridge S; Pirie A; Denny E; McCorry D; Khan KS
Health Technol Assess; 2018 May; 22(23):1-152. PubMed ID: 29737274
[TBL] [Abstract][Full Text] [Related]
12. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A
Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Drug Monitoring for Perampanel in Japanese Epilepsy Patients: Influence of Concomitant Antiepileptic Drugs.
Yamamoto Y; Usui N; Nishida T; Takahashi Y; Imai K; Kagawa Y; Inoue Y
Ther Drug Monit; 2017 Aug; 39(4):446-449. PubMed ID: 28703720
[TBL] [Abstract][Full Text] [Related]
14. Lacosamide add-on therapy for focal epilepsy.
Babar RK; Bresnahan R; Gillespie CS; Michael BD
Cochrane Database Syst Rev; 2021 May; 5(5):CD008841. PubMed ID: 33998660
[TBL] [Abstract][Full Text] [Related]
15. Switching from traditional sodium channel blockers to lacosamide in patients with epilepsy.
Kim DW; Kim HK; Bae EK
Seizure; 2019 Feb; 65():172-175. PubMed ID: 30721874
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of the dose and blood concentration of lacosamide in Japanese pediatric patients with epilepsy: A cohort study.
Ishikawa N; Eguchi Y; Izumo H; Tateishi Y; Tani H; Kobayashi Y; Okada S
Epilepsy Behav; 2022 Apr; 129():108614. PubMed ID: 35203014
[TBL] [Abstract][Full Text] [Related]
17. Lacosamide in patients with epilepsy of cerebrovascular etiology.
Rosenow F; Brandt C; Bozorg A; Dimova S; Steiniger-Brach B; Zhang Y; Ferrò B; Holmes GL; Kälviäinen R
Acta Neurol Scand; 2020 Jun; 141(6):473-482. PubMed ID: 32068241
[TBL] [Abstract][Full Text] [Related]
18. Sodium Channel Blockers in the Treatment of Epilepsy.
Brodie MJ
CNS Drugs; 2017 Jul; 31(7):527-534. PubMed ID: 28523600
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of therapeutic drug level monitoring of phenobarbital, phenytoin and carbamazepine in Iranian epileptic patients.
Babaei A; Eslamai MH
Int J Clin Pharmacol Ther; 2007 Feb; 45(2):121-5. PubMed ID: 17323792
[TBL] [Abstract][Full Text] [Related]
20. A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy.
Jannuzzi G; Cian P; Fattore C; Gatti G; Bartoli A; Monaco F; Perucca E
Epilepsia; 2000 Feb; 41(2):222-30. PubMed ID: 10691121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
